ReviewFrontiers in oncology2014
Emerging insights into barriers to effective brain tumor therapeutics.
Review in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 145 citations in OpenAlex.
- Identifying new therapeutics for focused ultrasound-enhanced drug delivery in the management of glioblastoma.Frontiers in oncology · 2025Review
- Local delivery of doxorubicin prodrug via lipid nanocapsule-based hydrogel for the treatment of glioblastoma.Drug delivery and translational research · 2024Article
- Overcoming the Blood-Brain Barrier: Multifunctional Nanomaterial-Based Strategies for Targeted Drug Delivery in Neurological Disorders.Small science · 2024Article
- Carrier-Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Protein Engineering and High-Throughput Screening by Yeast Surface Display: Survey of Current Methods.Small science · 2023Article
- Review
- Review
- A Highly Translatable Dual-arm Local Delivery Strategy To Achieve Widespread Therapeutic Coverage in Healthy and Tumor-bearing Brain Tissues.Small (Weinheim an der Bergstrasse, Germany) · 2023Article
- Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.Neuro-oncology · 2022Article
- Arming Immune Cell Therapeutics with Polymeric Prodrugs.Advanced healthcare materials · 2022Article
- Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance.Frontiers in cell and developmental biology · 2022Review
- Novel Treatment Approaches for Brain Tumour from a Blood-Brain Barrier Perspective.Handbook of experimental pharmacology · 2022Article
- Towards controlled drug delivery in brain tumors with microbubble-enhanced focused ultrasound.Advanced drug delivery reviews · 2022Review
- Article
- Pyrazolo[3,4-Brain sciences · 2021Article
- A New Chalcone Derivative with Promising Antiproliferative and Anti-Invasion Activities in Glioblastoma Cells.Molecules (Basel, Switzerland) · 2021Article
- Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme.Cancers · 2021Review
- Nanogels as a Versatile Drug Delivery System for Brain Cancer.Gels (Basel, Switzerland) · 2021Review
- Trafficking of JC virus-like particles across the blood-brain barrier.Nanoscale advances · 2021Article
- Insights into Multifunctional Nanoparticle-Based Drug Delivery Systems for Glioblastoma Treatment.Molecules (Basel, Switzerland) · 2021Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
There is great promise that ongoing advances in the delivery of therapeutics to the central nervous system (CNS) combined with rapidly expanding knowledge of brain tumor patho-biology will provide new, more effective therapies. Brain tumors that form from brain cells, as opposed to those that come from other parts of the body, rarely metastasize outside of the CNS. Instead, the tumor cells invade deep into the brain itself, causing disruption in brain circuits, blood vessel and blood flow changes, and tissue swelling. Patients with the most common and deadly form, glioblastoma (GBM) rarely live more than 2 years even with the most aggressive treatments and often with devastating neurological consequences. Current treatments include maximal safe surgical removal or biopsy followed by radiation and chemotherapy to address the residual tumor mass and invading tumor cells. However, delivering effective and sustained treatments to these invading cells without damaging healthy brain tissue is a major challenge and focus of the emerging fields of nanomedicine and viral and cell-based therapies. New treatment strategies, particularly those directed against the invasive component of this devastating CNS disease, are sorely needed. In this review, we (1) discuss the history and evolution of treatments for GBM, (2) define and explore three critical barriers to improving therapeutic delivery to invasive brain tumors, specifically, the neuro-vascular unit as it relates to the blood brain barrier, the extra-cellular space in regard to the brain penetration barrier, and the tumor genetic heterogeneity and instability in association with the treatment efficacy barrier, and (3) identify promising new therapeutic delivery approaches that have the potential to address these barriers and create sustained, meaningful efficacy against GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.